Exelixis (EXEL) Stock Analysis & AI Equity Report
Exelixis (EXEL) overview
Exelixis (EXEL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 2,320m and operating profit of USD 872m; the year-end share price was 43.58 USD and market capitalisation was USD 11,439m. Exelixis is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Exelixis's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Exelixis
Exelixis is an oncology company that discovers, develops and commercializes medicines for cancer. Its U.S. portfolio includes CABOMETYX and COMETRIQ, while partners including Ipsen and Takeda commercialize certain products in other territories. The company also advances clinical and research programs, including drug candidates and combination regimens for different cancer types.
Generate the Exelixis report
Exelixis is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Exelixis and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Exelixis
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.